vs
布鲁克(BRKR)与STANDARD BIOTOOLS INC.(LAB)财务数据对比。点击上方公司名可切换其他公司
布鲁克的季度营收约是STANDARD BIOTOOLS INC.的303.3倍($977.2M vs $3.2M)。STANDARD BIOTOOLS INC.净利率更高(598.5% vs 2.7%,领先595.8%)。STANDARD BIOTOOLS INC.同比增速更快(262.0% vs -0.2%)。布鲁克自由现金流更多($207.2M vs $-1.7M)。过去两年布鲁克的营收复合增速更高(16.4% vs -73.4%)
布鲁克公司是美国科学仪器制造商,总部位于马萨诸塞州比勒里卡,为公开上市企业。公司产品服务于分子与材料研究、工业及应用分析领域,旗下设有布鲁克科学仪器、布鲁克能源与超导技术(BEST)两大业务板块。
Standard BioTools(原Fluidigm公司)是一家美国生命科学工具企业,主营流式细胞术与组织成像分析用质谱流式系统,以及配套的检测试剂盒与试剂,同时供应自动化基因组分析仪器、各类微流控芯片(又称集成流体电路)及配套试剂耗材,全系列产品及应用场景均可提供定制检测方案与相关服务。
BRKR vs LAB — 直观对比
营收规模更大
BRKR
是对方的303.3倍
$3.2M
营收增速更快
LAB
高出262.3%
-0.2%
净利率更高
LAB
高出595.8%
2.7%
自由现金流更多
BRKR
多$208.9M
$-1.7M
两年增速更快
BRKR
近两年复合增速
-73.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | ||
|---|---|---|
| 营收 | $977.2M | $3.2M |
| 净利润 | $26.0M | $19.3M |
| 毛利率 | 46.0% | 83.5% |
| 营业利润率 | 7.8% | -578.6% |
| 净利率 | 2.7% | 598.5% |
| 营收同比 | -0.2% | 262.0% |
| 净利润同比 | 89.8% | 156.6% |
| 每股收益(稀释后) | $0.10 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
BRKR
LAB
| Q4 25 | $977.2M | $3.2M | ||
| Q3 25 | $860.5M | $19.6M | ||
| Q2 25 | $797.4M | $21.8M | ||
| Q1 25 | $801.4M | $40.8M | ||
| Q4 24 | $979.6M | $890.0K | ||
| Q3 24 | $864.4M | $22.1M | ||
| Q2 24 | $800.7M | $22.5M | ||
| Q1 24 | $721.7M | $45.5M |
净利润
BRKR
LAB
| Q4 25 | $26.0M | $19.3M | ||
| Q3 25 | $-59.6M | $-34.7M | ||
| Q2 25 | $7.6M | $-33.5M | ||
| Q1 25 | $17.4M | $-26.0M | ||
| Q4 24 | $13.7M | $-34.1M | ||
| Q3 24 | $40.9M | $-26.9M | ||
| Q2 24 | $7.6M | $-45.7M | ||
| Q1 24 | $50.9M | $-32.2M |
毛利率
BRKR
LAB
| Q4 25 | 46.0% | 83.5% | ||
| Q3 25 | 44.1% | 48.5% | ||
| Q2 25 | 44.9% | 48.8% | ||
| Q1 25 | 48.8% | 48.4% | ||
| Q4 24 | 50.4% | -202.8% | ||
| Q3 24 | 48.4% | 54.9% | ||
| Q2 24 | 48.0% | 46.1% | ||
| Q1 24 | 48.9% | 53.1% |
营业利润率
BRKR
LAB
| Q4 25 | 7.8% | -578.6% | ||
| Q3 25 | -6.0% | -168.5% | ||
| Q2 25 | 1.5% | -118.1% | ||
| Q1 25 | 4.0% | -80.8% | ||
| Q4 24 | 7.4% | -1162.1% | ||
| Q3 24 | 7.9% | -120.9% | ||
| Q2 24 | 6.0% | -134.5% | ||
| Q1 24 | 9.0% | -132.2% |
净利率
BRKR
LAB
| Q4 25 | 2.7% | 598.5% | ||
| Q3 25 | -6.9% | -177.4% | ||
| Q2 25 | 1.0% | -153.7% | ||
| Q1 25 | 2.2% | -63.8% | ||
| Q4 24 | 1.4% | -3828.3% | ||
| Q3 24 | 4.7% | -122.0% | ||
| Q2 24 | 0.9% | -203.3% | ||
| Q1 24 | 7.1% | -70.6% |
每股收益(稀释后)
BRKR
LAB
| Q4 25 | $0.10 | $0.05 | ||
| Q3 25 | $-0.41 | $-0.09 | ||
| Q2 25 | $0.05 | $-0.09 | ||
| Q1 25 | $0.11 | $-0.07 | ||
| Q4 24 | $0.09 | $-0.06 | ||
| Q3 24 | $0.27 | $-0.07 | ||
| Q2 24 | $0.05 | $-0.12 | ||
| Q1 24 | $0.35 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $298.8M | $120.9M |
| 总债务越低越好 | $1.9B | — |
| 股东权益账面价值 | $2.5B | $424.3M |
| 总资产 | $6.2B | $567.8M |
| 负债/权益比越低杠杆越低 | 0.76× | — |
8季度趋势,按日历期对齐
现金及短期投资
BRKR
LAB
| Q4 25 | $298.8M | $120.9M | ||
| Q3 25 | $293.1M | $129.4M | ||
| Q2 25 | $92.0M | $158.6M | ||
| Q1 25 | $184.2M | $150.9M | ||
| Q4 24 | $183.4M | $166.7M | ||
| Q3 24 | $148.1M | $210.6M | ||
| Q2 24 | $169.7M | $269.8M | ||
| Q1 24 | $340.1M | $287.1M |
总债务
BRKR
LAB
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | $299.0K | ||
| Q3 24 | $2.3B | $55.2M | ||
| Q2 24 | $2.2B | $55.1M | ||
| Q1 24 | $1.4B | $55.0M |
股东权益
BRKR
LAB
| Q4 25 | $2.5B | $424.3M | ||
| Q3 25 | $2.4B | $399.7M | ||
| Q2 25 | $1.8B | $424.5M | ||
| Q1 25 | $1.8B | $454.6M | ||
| Q4 24 | $1.8B | $471.7M | ||
| Q3 24 | $1.8B | $489.3M | ||
| Q2 24 | $1.8B | $510.3M | ||
| Q1 24 | $1.4B | $577.3M |
总资产
BRKR
LAB
| Q4 25 | $6.2B | $567.8M | ||
| Q3 25 | $6.4B | $539.6M | ||
| Q2 25 | $6.3B | $557.0M | ||
| Q1 25 | $5.9B | $579.6M | ||
| Q4 24 | $5.8B | $612.3M | ||
| Q3 24 | $6.1B | $681.5M | ||
| Q2 24 | $5.9B | $708.7M | ||
| Q1 24 | $4.5B | $777.7M |
负债/权益比
BRKR
LAB
| Q4 25 | 0.76× | — | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 1.34× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 1.18× | 0.00× | ||
| Q3 24 | 1.27× | 0.11× | ||
| Q2 24 | 1.21× | 0.11× | ||
| Q1 24 | 0.97× | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $229.8M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $207.2M | $-1.7M |
| 自由现金流率自由现金流/营收 | 21.2% | -51.7% |
| 资本支出强度资本支出/营收 | 2.3% | 14.8% |
| 现金转化率经营现金流/净利润 | 8.84× | -0.06× |
| 过去12个月自由现金流最近4个季度 | $43.3M | $-82.6M |
8季度趋势,按日历期对齐
经营现金流
BRKR
LAB
| Q4 25 | $229.8M | $-1.2M | ||
| Q3 25 | $-33.2M | $-22.2M | ||
| Q2 25 | $-127.5M | $-20.7M | ||
| Q1 25 | $65.0M | $-30.3M | ||
| Q4 24 | $190.0M | $-14.1M | ||
| Q3 24 | $38.4M | $-27.9M | ||
| Q2 24 | $1.1M | $-39.0M | ||
| Q1 24 | $21.8M | $-62.5M |
自由现金流
BRKR
LAB
| Q4 25 | $207.2M | $-1.7M | ||
| Q3 25 | $-54.1M | $-23.1M | ||
| Q2 25 | $-148.8M | $-22.6M | ||
| Q1 25 | $39.0M | $-35.3M | ||
| Q4 24 | $153.3M | $-17.4M | ||
| Q3 24 | $5.8M | $-30.1M | ||
| Q2 24 | $-23.5M | $-41.0M | ||
| Q1 24 | $400.0K | $-63.3M |
自由现金流率
BRKR
LAB
| Q4 25 | 21.2% | -51.7% | ||
| Q3 25 | -6.3% | -118.1% | ||
| Q2 25 | -18.7% | -103.6% | ||
| Q1 25 | 4.9% | -86.6% | ||
| Q4 24 | 15.6% | -1959.7% | ||
| Q3 24 | 0.7% | -136.4% | ||
| Q2 24 | -2.9% | -182.2% | ||
| Q1 24 | 0.1% | -138.9% |
资本支出强度
BRKR
LAB
| Q4 25 | 2.3% | 14.8% | ||
| Q3 25 | 2.4% | 4.5% | ||
| Q2 25 | 2.7% | 8.7% | ||
| Q1 25 | 3.2% | 12.4% | ||
| Q4 24 | 3.7% | 380.0% | ||
| Q3 24 | 3.8% | 10.2% | ||
| Q2 24 | 3.1% | 8.6% | ||
| Q1 24 | 3.0% | 1.7% |
现金转化率
BRKR
LAB
| Q4 25 | 8.84× | -0.06× | ||
| Q3 25 | — | — | ||
| Q2 25 | -16.78× | — | ||
| Q1 25 | 3.74× | — | ||
| Q4 24 | 13.87× | — | ||
| Q3 24 | 0.94× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRKR
| Bsi Nano | $309.1M | 32% |
| Bsi Biospin | $267.0M | 27% |
| Other | $179.9M | 18% |
| Transferred Over Time | $142.5M | 15% |
| Energy And Supercon Technologies | $69.5M | 7% |
LAB
暂无分部数据